Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
antihypertensive drugs
Biotech
AstraZeneca's $1.3B bet reduced BP by 14 mmHg over 12 weeks
The Big Pharma announced last month that the study had hit its primary endpoint.
James Waldron
Nov 10, 2025 6:15am
AstraZeneca's $1.3B bet yields 2nd phase 3 blood pressure win
Oct 7, 2025 4:01am
Novo Nordisk vs KBP: From $1.3B deal to legal battlefield
Oct 2, 2025 3:00am
With no Tryvio buyer, Idorsia recoups $100M from Viatris deal
Feb 26, 2025 7:00am
J&J hands back $230M blood pressure drug with approval in sight
Sep 6, 2023 6:20am
Mineralys upsizes IPO to raise $192M for race with AstraZeneca
Feb 10, 2023 9:10am
